Monoclonal antibody (mAb) therapy is currently given to non-hospitalized persons with early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mild to moderate coronavirus ...
In a recent study published in the Annals of Internal Medicine, researchers assess the efficacy of monoclonal antibodies (mAbs) in treating coronavirus disease 2019 (COVID-19) caused by different ...
NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have signed a broad, global collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results